News

Pixyl, Brainomix Partner on MRI Software to Help in Diagnosis of MS

In a new collaboration, Brainomix will distribute in Europe a software solution developed by Pixyl that uses deep learning to improve the diagnosis and monitoring of multiple sclerosis (MS) via MRI scans. According to the partners, Pixyl‘s technology can detect abnormalities on magnetic resonance imaging or MRI…

Switching to Ocrevus Over Other MS Therapies Means Fewer Relapses

People with relapsing-remitting multiple sclerosis (RRMS) who switch to Ocrevus (ocrelizumab) after discontinuing Gilenya (fingolimod) have fewer relapses than those who switch to Mavenclad (cladribine) or Tysabri (natalizumab), according to a new study. Rates of disability worsening were similar for Ocrevus and Tysabri, but patients who switched…

How Nasal Foralumab Affects Healthy Immune System: Study

Foralumab nasal spray, an experimental therapy by Tiziana Life Sciences that’s being tested for multiple sclerosis and other autoimmune and nervous system diseases, was found to be safe and able to modulate the immune system in healthy volunteers, a study has found. Researchers failed to detect antibodies…

More Inflammation Biomarkers in Spinal Fluid of PPMS Patients: Study

Individuals with primary progressive multiple sclerosis (PPMS) have significantly higher concentrations of specific inflammation biomarkers in their spinal fluid than healthy people, an exploratory study shows. For most biomarkers, levels in PPMS patients were comparable to or lower than those seen in people with relapsing-remitting multiple sclerosis (RRMS).

Climate Change Risk to MS Patients: Worse Symptoms, More Relapses

Temperature variability and increasing exposure to airborne pollutants — both consequences of climate change — can worsen disease symptoms and risk relapses in people with multiple sclerosis (MS), according to a recent review study. Unwanted effects of environmental change were also linked to a number of other neurological conditions,…

Add-on Supplement May Bolster Interferon Therapies for RRMS

A dietary supplement called Neuroaspis plp10 significantly lowered relapse rates and slowed disability progression among people with relapsing-remitting multiple sclerosis (RRMS) on interferon beta medications, according to a small clinical trial in Greece. “The results of this study suggest that Neuroaspis plp10 may offer greater benefit to patients with RRMS…

Panel Calls for New Way to Classify MS Based on Underlying Biology

An international panel is calling for new methods to classify multiple sclerosis (MS) that reflect the disease’s underlying biology, rather than differences in clinical presentation. The approach would fundamentally change how patients, clinicians, and other stakeholders understand and describe the disease, but would enable the development of biologically based…

2 Years of Vidofludimus Calcium Thwarts Disability Progression: Data

Most adults with relapsing-remitting multiple sclerosis (RRMS) who received Immunic Therapeutics‘ investigational therapy vidofludimus calcium have had no confirmed disability progression after two years of treatment. That’s according to new interim data from the open-label extension portion of the EMPhASIS trial, which has been running for nearly…

Fountain Health Now Fully Covers Cost of Combinostics’ Tests

Insurer Fountain Health now will fully cover Combinostics’ artificial intelligence (AI)-based tools to support the early detection, differential diagnosis, and prediction of progression in patients with neurodegenerative disorders such as multiple sclerosis (MS). The decision to cover the company’s cloud-based AI platforms, cMRI and cDSI,…

How Stem Cell Transplant Can ‘Reset’ Immune System in MS: Study

Following an autologous hematopoietic stem cell transplant (aHSCT) in people with multiple sclerosis (MS), the population of “naïve” T-cells — components of the immune system that enable the body to fight off new, unrecognized infections — is completely renewed but some memory T-cells, which are responsible for rapid responses…

Treatments Seen to Account for Largest Part of MS Financial Burden

Medications account for the majority of costs related to managing multiple sclerosis (MS) in Italy, and secondary-progressive MS (SPMS) is associated with higher treatment and healthcare costs than those for relapsing-remitting multiple sclerosis (RRMS), a study looking at real-world data reported. “A bigger healthcare resource consumption was retrieved for…

Rituximab Doses for MS Might Be Best Timed By Measuring B-cells

Timing doses of rituximab by measuring B-cell counts is a more tailored approach to treatment, and it effectively reduces relapses and disability progression in multiple sclerosis (MS), according to a small study in patients with active disease. This tailored approach allowed patients to receive less frequent doses if their B-cell counts…

Dietary Changes Can Help Ease Fatigue, Improve Quality of Life

Dietary interventions may help ease fatigue and improve quality of life in people with multiple sclerosis (MS), although it doesn’t seem to impact disability progression, according to a new analysis. Researchers emphasized that it’s difficult to draw solid conclusions about the impact of diet in MS because there haven’t…

Expert Voices: What Causes Multiple Sclerosis?

In this installment of our “Expert Voices” series, Multiple Sclerosis News Today asked Brandon Beaber, MD, to answer some of your questions about research into the causes of multiple sclerosis (MS). Beaber is a board-certified neurologist and MS specialist. He makes videos about MS on YouTube and…

Saint Louis University Opens Neuroscience Research Institute

With an overarching goal of improving patients’ health and life quality, Saint Louis University (SLU) has opened an institute for neuroscience researchers working in a variety of fields to study disorders of the central nervous system, including multiple sclerosis (MS). The Institute for Translational Neuroscience (ITN), an outgrowth of the…

NMSS Grant Supports Work Into Epstein-Barr Virus as MS Trigger

A National Multiple Sclerosis Society grant is supporting an Australian-led research team aiming to better understand how the Epstein-Barr virus (EBV) may be acting as a trigger for multiple sclerosis (MS). The funding will particularly be used to understand what molecules are being targeted by lymphocytes, immune cells that…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here